{"id":"covid-19-convalescent-plasma","safety":{"commonSideEffects":[{"rate":"null","effect":"Thrombosis"},{"rate":"null","effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL2108772","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Convalescent plasma contains antibodies that have been shown to neutralize the SARS-CoV-2 virus. These antibodies can help to reduce the severity and duration of COVID-19 symptoms, and may also help to prevent severe illness and death.","oneSentence":"COVID-19 convalescent plasma is a treatment that uses antibodies from recovered patients to help the body fight off the SARS-CoV-2 virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:29:09.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19 in patients with severe or critical illness"}]},"trialDetails":[{"nctId":"NCT04333251","phase":"PHASE1","title":"Study Testing Convalescent Plasma vs Best Supportive Care","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2020-04-17","conditions":"Pneumonia, Interstitial","enrollment":""},{"nctId":"NCT04411602","phase":"PHASE1","title":"Intermediate IND Severe Illness COVID-19 CP","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2020-04-07","conditions":"Severe Acute Respiratory Syndrome, COVID","enrollment":""},{"nctId":"NCT04497779","phase":"","title":"Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-07-13","conditions":"Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed","enrollment":95},{"nctId":"NCT04803370","phase":"NA","title":"Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma","status":"COMPLETED","sponsor":"Hospital Son Llatzer","startDate":"2020-07-08","conditions":"Covid19","enrollment":55},{"nctId":"NCT04345523","phase":"PHASE2","title":"Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients","status":"COMPLETED","sponsor":"Cristina Avendaño Solá","startDate":"2020-04-03","conditions":"COVID-19","enrollment":350},{"nctId":"NCT04408209","phase":"NA","title":"Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2020-04-23","conditions":"COVID-19 Infection","enrollment":60},{"nctId":"NCT04558476","phase":"PHASE2","title":"Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation","status":"COMPLETED","sponsor":"University of Liege","startDate":"2020-09-11","conditions":"Covid19, Mechanical Ventilation Complication, Corona Virus Infection","enrollment":475},{"nctId":"NCT05271929","phase":"PHASE3","title":"Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19","status":"TERMINATED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2022-04-01","conditions":"COVID-19","enrollment":120},{"nctId":"NCT04513158","phase":"PHASE2","title":"Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection","status":"TERMINATED","sponsor":"Joseph M. Flynn, D.O., MPH","startDate":"2020-08-14","conditions":"Covid19","enrollment":2},{"nctId":"NCT04359810","phase":"PHASE2","title":"Plasma Therapy of COVID-19 in Severely Ill Patients","status":"COMPLETED","sponsor":"Max O'Donnell","startDate":"2020-04-21","conditions":"SARS-CoV-2 Infection","enrollment":223},{"nctId":"NCT04390503","phase":"PHASE2","title":"Convalescent Plasma for Early Treatment of COVID-19","status":"TERMINATED","sponsor":"Andrew Eisenberger","startDate":"2021-03-12","conditions":"SARS-CoV 2, COVID-19","enrollment":223},{"nctId":"NCT04973488","phase":"NA","title":"Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients","status":"COMPLETED","sponsor":"Novacescu Alexandru","startDate":"2020-07-25","conditions":"COVID-19 Pneumonia, COVID-19 Respiratory Infection, Acute Respiratory Failure","enrollment":38},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04345991","phase":"PHASE2","title":"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-15","conditions":"Covid19","enrollment":120},{"nctId":"NCT04516954","phase":"EARLY_PHASE1","title":"Convalescent Plasma for COVID-19 Patients","status":"COMPLETED","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2020-08-01","conditions":"COVID 19","enrollment":4},{"nctId":"NCT04521036","phase":"PHASE1","title":"Convalescent Plasma for COVID-19 Patients (CPCP)","status":"COMPLETED","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2020-12-01","conditions":"COVID 19","enrollment":4},{"nctId":"NCT04397523","phase":"NA","title":"Efficacy and Safety of COVID-19 Convalescent Plasma","status":"COMPLETED","sponsor":"Institute for Transfusion Medicine of RNM","startDate":"2020-04-30","conditions":"Convalescent Plasma, COVID-19, SARS-CoV 2","enrollment":200},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT04351503","phase":"","title":"A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-04-09","conditions":"SARS Coronavirus (SARS-CoV-2) Infection","enrollment":126586},{"nctId":"NCT04354831","phase":"PHASE2","title":"Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2020-05-11","conditions":"COVID-19","enrollment":131},{"nctId":"NCT04545047","phase":"","title":"Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2020-05-01","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":5044},{"nctId":"NCT04377672","phase":"PHASE1","title":"Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-05-28","conditions":"SARS-CoV-2 Infection","enrollment":14},{"nctId":"NCT04340050","phase":"EARLY_PHASE1","title":"COVID-19 Convalescent Plasma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2020-04-10","conditions":"Coronavirus","enrollment":10},{"nctId":"NCT04360278","phase":"","title":"Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2020-04-21","conditions":"COVID-19","enrollment":258},{"nctId":"NCT04355897","phase":"EARLY_PHASE1","title":"CoVID-19 Plasma in Treatment of COVID-19 Patients","status":"COMPLETED","sponsor":"The Christ Hospital","startDate":"2020-04-28","conditions":"COVID 19","enrollment":22},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04956445","phase":"","title":"Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development","status":"UNKNOWN","sponsor":"Tulane University","startDate":"2020-03-17","conditions":"Covid19","enrollment":2000},{"nctId":"NCT04463823","phase":"","title":"\"NORPLASMA\" Covid-19 Convalescent Plasma Treatment Monitoring Study","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2020-07-06","conditions":"COVID","enrollment":500},{"nctId":"NCT04412486","phase":"EARLY_PHASE1","title":"COVID-19 Convalescent Plasma (CCP) Transfusion","status":"COMPLETED","sponsor":"Gailen D. Marshall Jr., MD PhD","startDate":"2020-06-01","conditions":"COVID-19","enrollment":86},{"nctId":"NCT05077930","phase":"PHASE2","title":"Convalescent Plasma Therapy for Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Tânia Portella Costa","startDate":"2022-01-06","conditions":"COVID-19, Convalescent Plasma, SARS-CoV-2","enrollment":38},{"nctId":"NCT04420988","phase":"","title":"Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Rutgers, The State University of New Jersey","startDate":"","conditions":"COVID-19, SARS-CoV 2, SARS-CoV Infection","enrollment":""},{"nctId":"NCT06084351","phase":"PHASE3","title":"Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection","status":"WITHDRAWN","sponsor":"Larkin Community Hospital","startDate":"2020-05-12","conditions":"Covid19","enrollment":""},{"nctId":"NCT04456413","phase":"PHASE2","title":"Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2020-11-06","conditions":"COVID-19","enrollment":21},{"nctId":"NCT04343755","phase":"PHASE2","title":"Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2020-04-09","conditions":"COVID-19","enrollment":52},{"nctId":"NCT04433910","phase":"PHASE2","title":"A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19","status":"COMPLETED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2020-08-30","conditions":"COVID-19","enrollment":106},{"nctId":"NCT05157165","phase":"","title":"Convalescent Plasma in Hospitalized COVID-19 Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Azienda Socio Sanitaria Territoriale di Mantova","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05905380","phase":"","title":"Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-03-02","conditions":"COVID-19 Convalescent Plasma Treatment","enrollment":200},{"nctId":"NCT05904067","phase":"NA","title":"A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-06-10","conditions":"COVID-19, Hematopoietic Stem Cell Transplantation","enrollment":72},{"nctId":"NCT04373460","phase":"PHASE2","title":"Convalescent Plasma to Limit SARS-CoV-2 Associated Complications","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-06-03","conditions":"SARS-CoV 2","enrollment":1225},{"nctId":"NCT04445207","phase":"","title":"Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Jonathan Gerber","startDate":"","conditions":"COVID, Sars-CoV2, Corona Virus Infection","enrollment":""},{"nctId":"NCT04360486","phase":"","title":"Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)","status":"NO_LONGER_AVAILABLE","sponsor":"U.S. Army Medical Research and Development Command","startDate":"","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":""},{"nctId":"NCT04434131","phase":"PHASE2","title":"Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2020-04-28","conditions":"COVID-19","enrollment":12},{"nctId":"NCT04363034","phase":"","title":"Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program","status":"NO_LONGER_AVAILABLE","sponsor":"University of Arkansas","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04884477","phase":"","title":"COVID-19 Infection in Patients Receiving Anti-CD20 Therapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-06-01","conditions":"COVID-19, Immunosuppressed Host, Convalescent Plasma","enrollment":342},{"nctId":"NCT05745753","phase":"NA","title":"Clinical and Imaging Biomarkers Associated With Plasma ad Cellular Determinants of Cardiovascular Disease at the Time of COVID 19","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-01-16","conditions":"Cardiovascular Diseases","enrollment":120},{"nctId":"NCT04364737","phase":"PHASE2","title":"CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-04-17","conditions":"COVID-19, Coronavirus, Coronavirus Infection","enrollment":941},{"nctId":"NCT04408040","phase":"PHASE2","title":"Use of Convalescent Plasma for COVID-19","status":"TERMINATED","sponsor":"Northside Hospital, Inc.","startDate":"2020-07-14","conditions":"COVID","enrollment":8},{"nctId":"NCT04362176","phase":"PHASE3","title":"Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2020-04-24","conditions":"COVID-19, Coronavirus, SARS-CoV-2","enrollment":974},{"nctId":"NCT05595538","phase":"EARLY_PHASE1","title":"Use of Multiple Doses of Convalescent Plasma in Mechanically Intubated Patients With COVID-19","status":"COMPLETED","sponsor":"Hospital Regional Dr. Rafael Estévez","startDate":"2020-06-06","conditions":"COVID-19","enrollment":30},{"nctId":"NCT04555109","phase":"","title":"Convalescent Plasma for COVID-19 Research Donor Study","status":"UNKNOWN","sponsor":"The Hospital for Sick Children","startDate":"2020-06-30","conditions":"Covid19","enrollment":1000},{"nctId":"NCT04891172","phase":"PHASE2, PHASE3","title":"Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients","status":"UNKNOWN","sponsor":"Dow University of Health Sciences","startDate":"2021-08-01","conditions":"Covid19","enrollment":310},{"nctId":"NCT04472572","phase":"","title":"Expanded Access to Convalescent Plasma for Treatment of COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Hackensack Meridian Health","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04421404","phase":"PHASE2","title":"Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients","status":"COMPLETED","sponsor":"Priscilla Hsue, MD","startDate":"2020-06-09","conditions":"COVID-19, Sars-CoV2","enrollment":34},{"nctId":"NCT04539275","phase":"PHASE3","title":"VA CoronavirUs Research and Efficacy Studies-1","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2020-11-16","conditions":"COVID-19","enrollment":75},{"nctId":"NCT04382651","phase":"PHASE2","title":"Study of Efficacy and Safety of MAS825 in Patients With COVID-19","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-11","conditions":"COVID-19 Pneumonia, Impaired Respiratory Function","enrollment":140},{"nctId":"NCT04345289","phase":"PHASE3","title":"Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia","status":"TERMINATED","sponsor":"Thomas Benfield","startDate":"2020-05-01","conditions":"COVID, Corona Virus Infection, Viral Pneumonia","enrollment":147},{"nctId":"NCT04382053","phase":"PHASE2","title":"Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-05-27","conditions":"COVID-19 Pneumonia, Impaired Respiratory Function","enrollment":143},{"nctId":"NCT04404608","phase":"","title":"Etiology of Lymphopenia in Covid19 Infection","status":"COMPLETED","sponsor":"Dr Medhat Khafagy","startDate":"2020-06-01","conditions":"Lymphopenia","enrollment":172},{"nctId":"NCT04535063","phase":"PHASE3","title":"Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno","startDate":"2020-04-18","conditions":"Covid19 Pneumonia","enrollment":200},{"nctId":"NCT04730401","phase":"PHASE2","title":"Convalescent Plasma in the Treatment of Covid-19","status":"UNKNOWN","sponsor":"Helsinki University Central Hospital","startDate":"2021-01-27","conditions":"Covid19","enrollment":390},{"nctId":"NCT04567173","phase":"PHASE2, PHASE3","title":"Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19","status":"TERMINATED","sponsor":"University of the Philippines","startDate":"2020-09-21","conditions":"Covid19","enrollment":44},{"nctId":"NCT04415086","phase":"PHASE2","title":"Treatment of Patients With COVID-19 With Convalescent Plasma","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-06-01","conditions":"COVID-19","enrollment":129},{"nctId":"NCT04385199","phase":"PHASE2","title":"Convalescent Plasma for Patients With COVID-19","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2020-05-04","conditions":"Coronavirus Infection, Coronavirus, COVID","enrollment":30},{"nctId":"NCT04323800","phase":"PHASE2","title":"Convalescent Plasma to Stem Coronavirus (CSSC-001)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-06-10","conditions":"Coronavirus, Convalescence","enrollment":180},{"nctId":"NCT04397757","phase":"PHASE1","title":"COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-05-13","conditions":"COVID-19","enrollment":80},{"nctId":"NCT04372979","phase":"PHASE3","title":"Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.","status":"TERMINATED","sponsor":"Direction Centrale du Service de Santé des Armées","startDate":"2020-09-14","conditions":"COVID-19","enrollment":18},{"nctId":"NCT04438057","phase":"PHASE2","title":"Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19","status":"COMPLETED","sponsor":"Metro Infectious Disease Consultants","startDate":"2020-08-12","conditions":"COVID-19","enrollment":103},{"nctId":"NCT04366245","phase":"PHASE1, PHASE2","title":"Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection","status":"COMPLETED","sponsor":"Andalusian Network for Design and Translation of Advanced Therapies","startDate":"2020-04-23","conditions":"SARS-CoV 2","enrollment":72},{"nctId":"NCT04642014","phase":"NA","title":"Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness","status":"TERMINATED","sponsor":"Wroclaw Medical University","startDate":"2020-12-22","conditions":"COVID-19 Convalescent Plasma Treatment","enrollment":396},{"nctId":"NCT04388527","phase":"PHASE1","title":"COVID-19 Convalescent Plasma for Mechanically Ventilated Population","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-04-30","conditions":"Covid-19","enrollment":32},{"nctId":"NCT04374565","phase":"PHASE2","title":"Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2020-05-05","conditions":"Corona Virus Infection, SARS-CoV 2, SARS Pneumonia","enrollment":29},{"nctId":"NCT04589949","phase":"PHASE3","title":"Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2020-10-12","conditions":"Covid19","enrollment":420},{"nctId":"NCT04342182","phase":"PHASE2, PHASE3","title":"Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2020-04-08","conditions":"COVID-19","enrollment":86},{"nctId":"NCT04721236","phase":"NA","title":"Early Use of Hyperimmune Plasma in COVID-19","status":"UNKNOWN","sponsor":"Catherine Klersy","startDate":"2020-11-19","conditions":"Covid19","enrollment":260},{"nctId":"NCT04432272","phase":"PHASE2","title":"ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)","status":"TERMINATED","sponsor":"Corewell Health East","startDate":"2020-07-16","conditions":"COVID-19, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections","enrollment":71},{"nctId":"NCT05247307","phase":"PHASE3","title":"Efficacy of the Infusion of Donor Plasma in COVID-19 Infection","status":"TERMINATED","sponsor":"Hospital Galdakao-Usansolo","startDate":"2020-03-31","conditions":"COVID-19","enrollment":93},{"nctId":"NCT04348656","phase":"PHASE3","title":"CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)","status":"TERMINATED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2020-03-14","conditions":"COVID-19","enrollment":940},{"nctId":"NCT04428021","phase":"PHASE2","title":"Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure","status":"COMPLETED","sponsor":"A.O.U. Città della Salute e della Scienza","startDate":"2020-06-15","conditions":"COVID-19","enrollment":180},{"nctId":"NCT04681430","phase":"PHASE2","title":"Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2021-01-08","conditions":"Corona Virus Infection, SARS-CoV-2 Infection, SARS-CoV-2 PCR Test Positive","enrollment":22},{"nctId":"NCT04649879","phase":"PHASE2, PHASE3","title":"Convalescent Plasma for Treatment of COVID-19","status":"COMPLETED","sponsor":"Joakim Dillner","startDate":"2020-12-03","conditions":"Covid19","enrollment":59},{"nctId":"NCT05200754","phase":"PHASE2","title":"Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High-Risk Patients With COVID-19","status":"UNKNOWN","sponsor":"Carsten Müller-Tidow","startDate":"2020-09-03","conditions":"SARS-CoV-2 Infection","enrollment":174},{"nctId":"NCT05184127","phase":"PHASE2","title":"Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19","status":"COMPLETED","sponsor":"National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia","startDate":"2021-04-27","conditions":"COVID-19","enrollment":156},{"nctId":"NCT04502472","phase":"PHASE2, PHASE3","title":"Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma","status":"TERMINATED","sponsor":"Inova Health Care Services","startDate":"2020-06-06","conditions":"Covid-19","enrollment":109},{"nctId":"NCT04390178","phase":"PHASE1, PHASE2","title":"Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Joakim Dillner","startDate":"2020-04-10","conditions":"COVID-19","enrollment":10},{"nctId":"NCT04392232","phase":"PHASE2","title":"A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection","status":"COMPLETED","sponsor":"TriHealth Inc.","startDate":"2020-05-05","conditions":"Coronavirus, COVID-19, Convalescent Plasma","enrollment":159},{"nctId":"NCT04344535","phase":"PHASE1, PHASE2","title":"Convalescent Plasma vs. Standard Plasma for COVID-19","status":"TERMINATED","sponsor":"Stony Brook University","startDate":"2020-04-08","conditions":"COVID","enrollment":82},{"nctId":"NCT04524507","phase":"PHASE2","title":"Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2020-08-27","conditions":"COVID-19","enrollment":56},{"nctId":"NCT04384497","phase":"PHASE1, PHASE2","title":"Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study","status":"COMPLETED","sponsor":"Joakim Dillner","startDate":"2020-05-07","conditions":"COVID-19","enrollment":10},{"nctId":"NCT04458363","phase":"EARLY_PHASE1","title":"Convalescent Plasma in Pediatric COVID-19","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-07-04","conditions":"COVID","enrollment":3},{"nctId":"NCT04347681","phase":"PHASE2","title":"Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19","status":"COMPLETED","sponsor":"King Fahad Specialist Hospital Dammam","startDate":"2020-04-18","conditions":"Convalescent Plasma for COVID 19","enrollment":575},{"nctId":"NCT04353206","phase":"EARLY_PHASE1","title":"Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure","status":"TERMINATED","sponsor":"Noah Merin","startDate":"2020-06-27","conditions":"Covid-19, Sars-CoV2","enrollment":6},{"nctId":"NCT04497324","phase":"PHASE2","title":"PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19","status":"COMPLETED","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2020-09-21","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04429854","phase":"PHASE2","title":"Donated Antibodies Working Against nCoV","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-05-02","conditions":"COVID-19","enrollment":483},{"nctId":"NCT04356534","phase":"NA","title":"Convalescent Plasma Trial in COVID -19 Patients","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2020-04-19","conditions":"SARS-CoV 2, COVID-19","enrollment":40},{"nctId":"NCT04355767","phase":"PHASE3","title":"Convalescent Plasma in Outpatients With COVID-19","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-08-11","conditions":"Covid19","enrollment":511},{"nctId":"NCT04425915","phase":"PHASE3","title":"Efficacy of Convalescent Plasma Therapy in Patients With COVID-19","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2020-06-14","conditions":"COVID","enrollment":400},{"nctId":"NCT05046652","phase":"","title":"Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series","status":"COMPLETED","sponsor":"Maranatha Christian University","startDate":"2020-04-01","conditions":"Infectious Disease","enrollment":8},{"nctId":"NCT04621123","phase":"PHASE2","title":"Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2020-11-10","conditions":"SARS-CoV-2 Infection, Safety and Efficacy","enrollment":384},{"nctId":"NCT04716556","phase":"NA","title":"TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients","status":"COMPLETED","sponsor":"Istituto Superiore di Sanità","startDate":"2020-07-16","conditions":"Covid19, Coronavirus Infection, Pneumonia, Viral","enrollment":474},{"nctId":"NCT04468009","phase":"PHASE2","title":"Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma","status":"COMPLETED","sponsor":"Hospital de Infecciosas Francisco Javier Muniz","startDate":"2020-06-25","conditions":"SARS-Associated Coronavirus, Covid19, SARS-CoV Infection","enrollment":134}],"_emaApprovals":[],"_faersSignals":[{"count":200,"reaction":"OFF LABEL USE"},{"count":70,"reaction":"DRUG INEFFECTIVE FOR UNAPPROVED INDICATION"},{"count":37,"reaction":"DRUG INEFFECTIVE"},{"count":35,"reaction":"COVID-19"},{"count":18,"reaction":"MATERNAL EXPOSURE DURING PREGNANCY"},{"count":17,"reaction":"COVID-19 PNEUMONIA"},{"count":14,"reaction":"FOETAL EXPOSURE DURING PREGNANCY"},{"count":13,"reaction":"BRONCHOPULMONARY ASPERGILLOSIS"},{"count":13,"reaction":"DEATH"},{"count":13,"reaction":"EXPOSURE DURING PREGNANCY"}],"_approvalHistory":[],"publicationCount":489,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CCP"],"phase":"phase_2","status":"active","brandName":"COVID-19 convalescent plasma","genericName":"COVID-19 convalescent plasma","companyName":"Lifefactors Zona Franca, SAS","companyId":"lifefactors-zona-franca-sas","modality":"Biologic","firstApprovalDate":"","aiSummary":"COVID-19 convalescent plasma is a treatment that uses antibodies from recovered patients to help the body fight off the SARS-CoV-2 virus. Used for Treatment of COVID-19 in patients with severe or critical illness.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}